Entero Therapeutics, Inc. announced a 1 for 3 reverse stock split of its common stock.
The reverse stock split aims to regain compliance with the Nasdaq Listing Rule 5550(a)(2).
The split will reduce the outstanding common stock from approximately 4.77 million shares to approximately 1.59 million shares.
Reverse Stock Split
1 for 3 reverse stock split to comply with Nasdaq listing requirements.
Stock Reduction
Outstanding common stock to be reduced from 4.77 million shares to 1.59 million shares.
Fractional Shares
Fractional shares to be converted to cash for stockholders.
- The reverse stock split will enhance the visibility and credibility of Entero Therapeutics on the Nasdaq market.
- Maintaining the Nasdaq listing is crucial for enhancing shareholder value and attracting more investors.
The reverse stock split is a strategic move by Entero Therapeutics to meet Nasdaq compliance and strengthen shareholder confidence in the company's performance and future prospects.